Last reviewed · How we verify
Diphyllin (diprophylline)
Diphyllin (diprophylline) is a small molecule drug that targets cAMP-specific 3',5'-cyclic phosphodiesterase 4B. Originally developed in the 1950s, it is an off-patent medication used to treat various respiratory conditions, including asthma, chronic bronchitis, and pulmonary emphysema. Diphyllin works by increasing the levels of cAMP in the body, which helps to relax airway muscles and improve breathing. It has a bioavailability of 90% and a half-life of 1.7 hours. As an off-patent medication, diphyllin is likely available in generic forms.
At a glance
| Generic name | diprophylline |
|---|---|
| Drug class | diprophylline |
| Target | cAMP-specific 3',5'-cyclic phosphodiesterase 4B |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 1951 |
Approved indications
- Asthma
- Asthma management
- Asthma night-time symptoms
- Asthma-chronic obstructive pulmonary disease overlap syndrome
- Bronchospasm
- Chronic bronchitis
- Pulmonary emphysema
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diphyllin CI brief — competitive landscape report
- Diphyllin updates RSS · CI watch RSS
- portfolio CI